We retrospectively analyzed the short-term outcome of the third-generation St. Jude Trifecta aortic valve.
Between December 2014 and December 2017, 177 patients (mean age 75 ± 7 years, 95 males, 82 females) underwent aortic valve replacement (AVR) with St. Jude Trifecta aortic valve and were followed up to 27 ± 9 months.
Operative mortality was 3.4% (1.7%, isolated AVR). Three-year survival was 84% ± 6%, freedom from cardiac death 98% ± 1%. Echocardiographic variables are reported in Table.
Trifecta valve provides favourable clinical outcome and hemodynamic performance. No early structural valve degeneration has been observed. Due to the minimal incidence of severe PPM and to the low value of mean trans-prosthetic gradient, Trifecta valve should be considered as one of the best options among the third generation biological prostheses. Longer follow-up is mandatory.
Table. Echocardiographic variables and clinical status
1Cardiac Surgery Division, Tor Vergata University Hospital, Rome, Italy Roma